STOK (STOCKS)
Stoke Therapeutics, Inc. Common Stock
$32.220000
-0.220000 (-0.68%)
Prev close: $32.440000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Ian Frederick Smith
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,846.02M
- Employees
- 128
- P/E (TTM)
- 49.16
- P/B (TTM)
- 5.80
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $205.63M |
| Benefits Costs and Expenses | $165.07M |
| Costs And Expenses | $165.07M |
| Nonoperating Income/Loss | $13.37M |
| Operating Expenses | $178.44M |
| Research and Development | $119.65M |
| Operating Income/Loss | $27.20M |
| Income/Loss From Continuing Operations After Tax | $40.57M |
| Income/Loss From Continuing Operations Before Tax | $40.57M |
| Interest Expense, Operating | $5.00K |
| Net Income/Loss | $40.57M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $40.57M |
| Net Income/Loss Available To Common Stockholders, Basic | $40.57M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.73 |
| Diluted Earnings Per Share | $0.68 |
| Basic Average Shares | 175,846,074 |
| Diluted Average Shares | 177,382,000 |
| Assets | $360.26M |
| Current Assets | $272.44M |
| Prepaid Expenses | $7.75M |
| Other Current Assets | $264.69M |
| Noncurrent Assets | $87.83M |
| Fixed Assets | $3.08M |
| Other Non-current Assets | $84.74M |
| Liabilities | $52.16M |
| Current Liabilities | $41.73M |
| Accounts Payable | $5.87M |
| Other Current Liabilities | $35.86M |
| Noncurrent Liabilities | $10.43M |
| Equity | $308.11M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $308.11M |
| Liabilities And Equity | $360.26M |
| Net Cash Flow From Operating Activities | $52.85M |
| Net Cash Flow From Operating Activities, Continuing | $52.85M |
| Net Cash Flow From Investing Activities | -$124.93M |
| Net Cash Flow From Investing Activities, Continuing | -$124.93M |
| Net Cash Flow From Financing Activities | $5.62M |
| Net Cash Flow From Financing Activities, Continuing | $5.62M |
| Net Cash Flow | -$66.47M |
| Net Cash Flow, Continuing | -$66.47M |
| Comprehensive Income/Loss | $40.60M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $40.85M |
| Other Comprehensive Income/Loss | $280.00K |